Avenda Health, a Culver City, CA-based AI healthcare company creating the future of personalized prostate cancer care, announced it has raised $10 million in Series B funding.
The round was led by VCapital, with participation from Plug & Play Ventures and Wealthing VC Club.
The capital will be used to accelerate the use of iQuest, an AI-enabled patient management software that identifies and visualizes a patient's prostate cancer. The funding will also be used to continue clinical evidence development.
Company: Avenda Health Inc.
Round: Series B
Funding Month: Aug 2022
Lead Investors: VCapital
Additional Investors: Plug & Play Ventures and Wealthing VC Club
Company Website: https://www.avendahealth.com/
Software Category: AI Healthcare
About the Company: Founded in 2017, Avenda Health is a breakthrough-designated, AI-enabled male 'lumpectomy' for prostate cancer. Its technology leverages machine learning to map cancer and real-time sensing to deliver precise interventions in a doctor's office. Using deep learning, Avenda Health software maps a patient's cancer in 3D, giving physicians precise information and the confidence to make care decisions. Avenda Health developed iQuest, which uses AI-deep learning to uncover cancer previously hidden within traditional MRI mapping and can be used by physicians to better plan treatments. The Avenda Health FocalPoint System powered by iQuest reimagines laser ablation with a system to treat prostate cancer in-office under ultrasound guidance. FocalPoint is FDA cleared for soft tissue ablation. Avenda Health aims to improve outcomes, preserve quality of life, and create a new standard of cancer care.